{"title":"Tranexamic acid for trauma: optimal timing of administration based on the CRASH-2 and CRASH-3 trials.","authors":"Itsuki Osawa, Tadahiro Goto, Ian Roberts","doi":"10.1093/bjs/znaf079","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tranexamic acid reduces bleeding deaths in trauma patients, but the treatment benefit depends on the time from injury. It is recommended that tranexamic acid be administered immediately and only within 3 h of injury; however, the optimal criteria have not been adequately studied.</p><p><strong>Methods: </strong>We applied machine learning-based causal forest models to investigate heterogeneity in the effects of tranexamic acid on 24-hour mortality rate conditional on covariates (for example age, sex, time from injury, systolic blood pressure, and Glasgow Coma Scale, GCS). We analysed data on 28 448 trauma patients in the CRASH-2 and CRASH-3 randomized trials. We used the policytree algorithm to determine the optimal criteria for tranexamic acid treatment.</p><p><strong>Results: </strong>The causal forest models showed heterogeneity in the effects of tranexamic acid on 24-hour mortality rate. The relative risk reduction was greatest in patients treated within 2 h of injury but thereafter decreased rapidly. The pattern was similar regardless of age or systolic blood pressure, although with decreasing GCS, the time to treatment effects were weaker, with benefits beyond 3 h. The largest absolute risk reductions were in patients with a low blood pressure and a low GCS when treated soon after injury. The optimal criterion was statistically determined as patients within 2 h of the injury or with GCS < 9.</p><p><strong>Conclusions: </strong>Tranexamic acid administration was found to be beneficial when given within 2 h of injury. In patients with severe traumatic brain injury, the treatment benefits may persist beyond the 2-hour window.</p>","PeriodicalId":136,"journal":{"name":"British Journal of Surgery","volume":"112 4","pages":""},"PeriodicalIF":8.6000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bjs/znaf079","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Tranexamic acid reduces bleeding deaths in trauma patients, but the treatment benefit depends on the time from injury. It is recommended that tranexamic acid be administered immediately and only within 3 h of injury; however, the optimal criteria have not been adequately studied.
Methods: We applied machine learning-based causal forest models to investigate heterogeneity in the effects of tranexamic acid on 24-hour mortality rate conditional on covariates (for example age, sex, time from injury, systolic blood pressure, and Glasgow Coma Scale, GCS). We analysed data on 28 448 trauma patients in the CRASH-2 and CRASH-3 randomized trials. We used the policytree algorithm to determine the optimal criteria for tranexamic acid treatment.
Results: The causal forest models showed heterogeneity in the effects of tranexamic acid on 24-hour mortality rate. The relative risk reduction was greatest in patients treated within 2 h of injury but thereafter decreased rapidly. The pattern was similar regardless of age or systolic blood pressure, although with decreasing GCS, the time to treatment effects were weaker, with benefits beyond 3 h. The largest absolute risk reductions were in patients with a low blood pressure and a low GCS when treated soon after injury. The optimal criterion was statistically determined as patients within 2 h of the injury or with GCS < 9.
Conclusions: Tranexamic acid administration was found to be beneficial when given within 2 h of injury. In patients with severe traumatic brain injury, the treatment benefits may persist beyond the 2-hour window.
期刊介绍:
The British Journal of Surgery (BJS), incorporating the European Journal of Surgery, stands as Europe's leading peer-reviewed surgical journal. It serves as an invaluable platform for presenting high-quality clinical and laboratory-based research across a wide range of surgical topics. In addition to providing a comprehensive coverage of traditional surgical practices, BJS also showcases emerging areas in the field, such as minimally invasive therapy and interventional radiology.
While the journal appeals to general surgeons, it also holds relevance for specialty surgeons and professionals working in closely related fields. By presenting cutting-edge research and advancements, BJS aims to revolutionize the way surgical knowledge is shared and contribute to the ongoing progress of the surgical community.